News | January 25, 2022
USFDA rejects Merck’s gefapixant; gain approval in Japan
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
Studies show significant reduction in pain and improved quality of life for patients treated with spinal cord stimulation compared to medication management alone
Companies plan to commercialize breath-based detection of lung infection and transplant rejection
Madhavbaug has a pan-India presence with a vast network of 272 clinics and two hospitals
UCB plans to submit regulatory applications in Q3 2022
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
The tele-heath market in India is expected to touch US $ 5.4 billion by 2025 and the adoption of tele-health has accelerated with the onset of Covid-19 in 2020. We caught up with Jeya Kumar, Founder and MD, RaphaCure, a prominent player in this segment and he outlined the opportunities that lie ahead for this segment
It is the first monoclonal antibody drug for use in any animal species
ICICI Direct gives a preview on the earnings narrative for Q3FY22
Subscribe To Our Newsletter & Stay Updated
